Home  »  Companies   »  Reata Pharmaceuticals Inc. (NASDAQ: RETA)’s Shar...

Reata Pharmaceuticals Inc. (NASDAQ: RETA)’s Share Price Jumped 20.37%, What’s Next? Heres Is A Hint: Don’t Be Too Excited

Reata Pharmaceuticals Inc. (NASDAQ:RETA) shares, rose in value on Wednesday, 05/24/23, with the stock price up by 20.37% to the previous day’s close as strong demand from buyers drove the stock to $95.36.

Actively observing the price movement in the last trading, the stock closed the session at $79.22, falling within a range of $85.30 and $96.115. The value of beta (5-year monthly) was 1.53. Referring to stock’s 52-week performance, its high was $106.69, and the low was $18.47. On the whole, RETA has fluctuated by -4.40% over the past month.

Unlock the Hottest Top 10 Penny Stocks Today! Discover Now

Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.

Gain Access to Top 10 Penny Stocks Now!.

Sponsored

With the market capitalization of Reata Pharmaceuticals Inc. currently standing at about $3.64 billion, investors are eagerly awaiting this quarter’s results, scheduled for May 10, 2023. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$2.84, which is expected to increase to -$1.91 for fiscal year -$10.28 and then to about -$4.33 by fiscal year 2024. Data indicates that the EPS growth is expected to be -20.40% in 2024, while the next year’s EPS growth is forecast to be 57.90%.

According to the average forecast, sales growth in current quarter could jump up 1.00%, compared to the corresponding quarter of last year. Wall Street analysts also predicted that in 2024, the company’s y-o-y revenues would reach $52.07 million, representing an increase of 2,249.70% from the revenues reported in the last year’s results.

Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that RETA’s technical picture suggests that short-term indicators denote the stock is a 50% Buy on average. However, medium term indicators have put the stock in the category of 100% Buy while long term indicators on average have been pointing out that it is a 100% Buy.

10 analyst(s) have assigned their ratings of the stock’s forecast evaluation on a scale of 1.00-5.00 to indicate a strong buy to a strong sell recommendation. The stock is rated as a Hold by 2 analyst(s), 7 recommend it as a Buy and 1 called the RETA stock Overweight. In the meantime, 0 analyst(s) believe the stock as Underweight and 0 think it is a Sell. Thus, investors eager to increase their holdings of the company’s stock will have an opportunity to do so as the average rating for the stock is Overweight.

The stock’s technical analysis shows that the PEG ratio is about 0, with the price of RETA currently trading nearly 3.12% and 2.97% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 57.24, while the 7-day volatility ratio is showing 5.73% which for the 30-day chart, stands at 5.28%. Furthermore, Reata Pharmaceuticals Inc. (RETA)’s beta value is 1.54, and its average true range (ATR) is 5.63. The company’s stock has been forecasted to trade at an average price of $112.70 over the course of the next 52 weeks, with a low of $80.00 and a high of $179.00. Based on these price targets, the low is 16.11% off current price, whereas the price has to move -87.71% to reach the yearly target high. Additionally, analysts’ median price of $107.00 is likely to be welcomed by investors because it represents a decrease of -12.21% from the current levels.

A comparison of Reata Pharmaceuticals Inc. (RETA) with its peers suggests the former has fared considerably weaker in the market. RETA showed an intraday change of 20.37% in last session, and over the past year, it grew by 238.16%%. On the other hand, the price of Omeros Corporation (OMER) has risen 0.81% on the day. The stock, however, is off 113.79% from where it was a year ago. Other than that, the overall performance of the S&P 500 during the last trading session shows that it lost -0.73%. Meanwhile, the Dow Jones Industrial Slipped by -0.77%.

Data on historical trading for Reata Pharmaceuticals Inc. (NASDAQ:RETA) indicates that the trading volumes over the past 10 days have averaged 1.1 million and over the past 3 months, they’ve averaged 1.42 million. According to company’s latest data on outstanding shares, there are 36.95 million shares outstanding.

Nearly 3.83% of Reata Pharmaceuticals Inc.’s shares belong to company insiders and institutional investors own 89.30% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 4.79 million shares as on Apr 27, 2023, resulting in a short ratio of 9.14. According to the data, the short interest in Reata Pharmaceuticals Inc. (RETA) stood at 12.77% of shares outstanding as of Apr 27, 2023; the number of short shares registered in Mar 30, 2023 reached 5.04 million. The stock has risen by 151.01% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the RETA stock heading into the next quarter.

Leave a Comment

Your email address will not be published. Required fields are marked *